First Person Enters Its Next Phase of Growth Following Early Think Fast™ Momentum

Promotional claims outpace evidence; only single-participant data and no financials disclosed.

What the company is saying

The company positions Think Fast™ as a premium functional coffee leveraging proprietary Crystallized Lion's Mane technology, highlighting it as one of First Person's fastest-growing products. Messaging centers on early consumer momentum and the product's integration into routines for focus, productivity, and mental performance, but omits any sales, revenue, or adoption figures. The announcement emphasizes preliminary scientific validation, citing a Peak Brain Institute evaluation using qEEG and IVA-2 testing, with observed improvements in attention and reaction time. The company admits these results are from a single unblinded participant, lacking placebo or control, and explicitly states they do not establish causation or clinical efficacy. Broader claims about expanding brand positioning into cognitive performance and active lifestyles are aspirational, with no disclosed execution milestones. The tone is highly positive and promotional, with no mention of financial performance, profitability, or operational risks.

What the data suggests

The only quantitative data are an approximately 26% increase in overall attention score and a 28% improvement in visual reaction time, both from a preliminary evaluation of a single unblinded participant. No placebo or regular-coffee control was used, and the company concedes these results do not establish causation or clinical efficacy. There are no disclosed financial metrics, such as revenue, sales growth, margins, or cash position. No period-over-period comparisons, customer adoption rates, or market share data are provided. The evidence base is extremely limited, with the scientific results not generalizable and the commercial claims unsupported by numbers. An independent analyst would conclude that the announcement lacks the necessary data to assess financial health, product adoption, or long-term viability.

Analysis

The announcement uses highly positive language to describe product momentum and scientific validation, but the actual evidence is extremely limited. The only numerical data comes from a preliminary evaluation involving a single unblinded participant, with no placebo or control, and the company itself admits these results do not establish causation or clinical efficacy. Claims of 'early consumer momentum' and 'fastest-growing products' are not supported by any sales, revenue, or adoption figures. Most key claims are forward-looking or aspirational, such as broadening brand positioning and targeting new market segments, with no disclosed milestones or timelines. There is no mention of profitability, revenue, or any financial metric, so the true signal cannot exceed weak_positive. The gap between narrative and evidence is wide, with promotional language unsupported by robust data.

Risk flags

• ●The scientific evidence is extremely weak, relying on a single unblinded participant without placebo or control, which means results are not statistically valid and cannot be generalized. This undermines claims of product efficacy and increases the risk of regulatory or consumer backlash if unsupported claims are promoted.
• ●No financial data is disclosed, including sales, revenue, or profitability, making it impossible to assess the company's financial health or growth trajectory. This lack of transparency is a material risk for investors seeking to evaluate operational viability.
• ●Promotional language about consumer momentum and product growth is not substantiated by any quantitative data, raising the risk of a credibility gap between narrative and reality. Without evidence, such claims may mislead stakeholders and expose the company to reputational risk.

Bottom line

This announcement is primarily promotional, offering only preliminary, non-generalizable scientific data and no financial disclosures. The company's claims of growth and consumer momentum are unsupported by sales or adoption figures, and the cited product evaluation lacks scientific rigor. Investors have no basis to assess financial performance or the likelihood of future success. For this update to be actionable, the company would need to release robust sales data, controlled clinical results, or clear operational milestones. The most important takeaway is that the gap between narrative and evidence remains wide, and there is no credible pathway to near-term value realization based on the information provided.

Announcement summary

(OTC:QRON) First Person, a cognitive performance and functional wellness company and a wholly owned subsidiary of Qrons, Inc., announced the next phase of its growth following early consumer momentum for Think Fast™, its premium functional coffee powered by proprietary Crystallized Lion's Mane technology. Think Fast™ has quickly become one of First Person's fastest-growing products, driven by consumers incorporating it into routines centered on focus, productivity, and mental performance. Think Fast™ was evaluated at the Peak Brain Institute using qEEG brain imaging and IVA-2 cognitive-performance testing. In a preliminary evaluation, measured before and after a single serving, observed changes included: an approximately 26% increase in overall attention score; an approximately 28% improvement in visual reaction time; and an increase in alpha peak frequency in brain regions associated with executive and language function. Preliminary results from one unblinded participant, without placebo or regular-coffee controls, do not establish causation or clinical efficacy and may not apply to others. Think Fast™ joins First Person's portfolio of targeted cognitive supplements, including Sunbeam, Golden Hour and Moonlight, designed to support different moments throughout the day, from focus and mental readiness to calm, recovery and rest. First Person is a wholly owned subsidiary of Qrons, Inc. (OTCMarkets: QRON), developing science-driven products designed to support focus, mental readiness and everyday performance.

Disagree with this article?